21Oct 2023
EFFICACY AND SAFETY OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS

EFFICACY AND SAFETY OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS

In a phase 3 clinical trial called DISCREET, apremilast, an oral immunomodulating drug, was tested for its effectiveness and safety in treating genital psoriasis. The study involved patients with moderate-to-severe genital psoriasis and revealed that 39.6% of those on apremilast achieved a significant improvement in their condition compared to 19.5% on a placebo. This marked a substantial treatment difference, with improvements in genital symptoms, skin involvement, and quality of life. Apremilast appears to be a promising oral systemic treatment for genital psoriasis, offering hope for patients with limited treatment options.

  • #dermatology

Like

Save

Share